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CRD summary
The objective was to assess the cost-effectiveness of clomiphene citrate and intra-uterine insemination, as first-line treatments for couples with unexplained infertility. The authors concluded that both treatments were unlikely to be costeffective. On the whole, the methods seem to have been appropriate and were relatively well reported. The authors' conclusions seem valid.
Type of economic evaluation
Cost-effectiveness analysis
Study objective
The objective was to assess the cost-effectiveness of clomiphene citrate and intra-uterine insemination, as first-line treatments for couples with unexplained infertility.
Interventions
The three interventions were clomiphene citrate, intra-uterine insemination, and expectant management. Clomiphene citrate was given as an oral dose of 50mg between days two and six of each treatment cycle, with the couple advised to have intercourse on cycle days 12 to 18. Intra-uterine insemination included the monitoring of mid-morning urinary luteinising hormone concentrations from day 12 of the cycle, with a single insemination performed 20 to 30 hours after detecting a surge in the hormone. Expectant management included general advice for regular intercourse.
Location/setting
UK (Scotland)/hospital.
Methods

Analytical approach:
The economic evaluation was undertaken alongside a clinical trial. The time horizon was six months. The authors reported that the perspective was that of the UK NHS.
Effectiveness data:
The effectiveness data came from a multi-centre randomised controlled trial (RCT; Bhattacharya, et al. 2008 , see 'Other Publications of Related Interest' below for bibliographic details). The sample size was 580 couples. An intention-totreat approach was taken, with four couples lost to follow-up. The main clinical effectiveness estimate was the number of live births.
Monetary benefit and utility valuations:
Not relevant.
Measure of benefit:
The measure of benefit was the live birth rate.
Cost data:
The analysis included the costs associated with staff, consumables, equipment, and overheads. Resource use and cost data were obtained by questionnaires completed at the five sites participating in the RCT. Equipment costs were
